Abstract
The disposition of the angiotensin II receptor antagonist L-158,809 was studied in male rats and female rhesus monkeys. Rats were dosed either intravenously or orally with 0.3 mg [3H]L-158,809/kg. The terminal half-life of L-158,809 was 7.6 +/- 3.1 hr. Plasma clearance was 45.5 +/- 15.9 ml/hr/kg, and the volume of distribution at steady state was 0.37 +/- 0.11 liter/kg. The drug was completely bioavailable in rats. After oral administration, the peak plasma concentration of L-158,809 was 0.70 +/- 0.21 micrograms/ml at 15 min; only the parent drug was observed in plasma. After an oral dose of 3.0 mg [3H]L-158,809/kg, the peak plasma concentration of 4.9 +/- 0.6 micrograms/ml occurred at 1 hr. By 24 hr, 53.3 +/- 9.9% of an intraduodenal dose of 0.3 mg [3H]L-158,809/kg was excreted into bile. L-158,809 and its tetrazole-N2-beta-glucuronide were the major biliary components. Rhesus monkeys were dosed orally and intravenously at 1.0 mg and 0.5 mg [3H]L-158,809/kg, respectively. The plasma concentrations of L-158,809 varied considerably between monkeys after oral administration. The peak concentration was 42 +/- 42 ng/ml at 30 min, and the bioavailability was 32.3 +/- 12.6%. Plasma clearance was 839 +/- 364 ml/hr/kg; the volume of distribution at steady state was 1.42 +/- 0.73 liter/kg. Besides the parent, the major metabolite in monkey plasma was the tetrazole-N2-glucuronide of L-158,809. Both species excreted > 10% of the dose in the urine after intravenous or oral dosing; most of the dose was excreted in the feces, indicating extensive biliary excretion.
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|